MediWound(MDWD) - 2022 Q1 - Quarterly Report

Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2021 Financial Results Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of$ 10 Million through Public Equity Of ering Conference Call Begins Today at 8:30 am ET YAVNE, Israel, March 17, 2022 -- MediWound Ltd. (Nasdaq: MDWD) (the "Company"), a fully-integrated biopharmaceutical company focused ...